SYBX
Synlogic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.17
−4.10%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 8.0K | 3.4M | 1.2M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | 8.0K | 3.4M | 1.2M |
| Operating Expenses | |||||
| R&D Expense | 94.0K | 43.0K | 9.2M | 44.0M | 52.0M |
| SG&A Expense | 3.7M | 3.5M | 6.6M | 14.6M | 16.6M |
| General & Admin Expense | 3.7M | 3.5M | 6.6M | 14.6M | 16.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 847.0K | 476.0K | 25.2M | — | — |
| Total Operating Expenses | 4.7M | 4.0M | 41.0M | 58.5M | 68.6M |
| Cost and Expenses | 4.7M | 4.0M | 41.0M | 58.5M | 68.6M |
| Operating Income (EBIT) | (4.7M) | (4.0M) | (41.0M) | (55.2M) | (67.4M) |
| Non-Operating | |||||
| Interest Income | 574.0K | 695.0K | 1.4M | 2.5M | 1.3M |
| Interest Expense | — | — | — | 1.0K | 2.0K |
| Net Interest Income | 574.0K | 695.0K | 1.4M | 2.5M | 1.3M |
| Other Non-Op Income/Expense | 4.0M | 3.0M | 17.6M | (2.1M) | 1.3M |
| Non-Operating Income (excl Interest) | (890.0K) | (476.0K) | (17.6M) | 2.1M | (1.3M) |
| EBT (Pre-Tax Income) | (655.0K) | (1.0M) | (23.4M) | (57.3M) | (66.1M) |
| Income Tax Expense | — | — | 5.0K | 14.0K | — |
| Bottom Line | |||||
| Net Income | (655.0K) | (1.0M) | (23.4M) | (57.3M) | (66.1M) |
| Earnings from Cont. Ops | (655.0K) | (1.0M) | (23.4M) | (57.3M) | (66.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (655.0K) | (1.0M) | (23.4M) | (57.3M) | (66.1M) |
| Per Share | |||||
| Basic EPS | ($0.05) | ($0.08) | ($1.92) | ($8.81) | ($13.57) |
| Diluted EPS | ($0.05) | ($0.08) | ($1.92) | ($8.81) | ($13.57) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.52 | $0.25 |
| Shares | |||||
| Basic Shares Outstanding | 12.4M | 12.3M | 12.2M | 6.5M | 4.8M |
| Diluted Shares Outstanding | 12.4M | 12.3M | 12.2M | 6.5M | 4.8M |
| Profitability Metrics | |||||
| EBITDA | (3.7M) | (3.5M) | (22.1M) | (55.3M) | (63.6M) |
| D&A | 86.8K | — | 1.3M | 2.0M | 2.5M |
| EBIT | (3.8M) | (3.5M) | (23.4M) | (57.3M) | (66.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026